Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 17;14(14):5098.
doi: 10.3390/jcm14145098.

Irisin Concentrations in Children and Adolescent Cancer Survivors and Their Relation to Metabolic, Bone, and Reproductive Profile: A Pilot Case-Control Study

Despoina Apostolaki  1 , Katerina Katsibardi  2 , Vasiliki Efthymiou  1   3 , Charikleia Stefanaki  1 , Aimilia Mantzou  4 , Stavroula Papadodima  5 , George P Chrousos  3 , Antonis Kattamis  2   3 , Flora Bacopoulou  1   3
Affiliations

Irisin Concentrations in Children and Adolescent Cancer Survivors and Their Relation to Metabolic, Bone, and Reproductive Profile: A Pilot Case-Control Study

Despoina Apostolaki et al. J Clin Med. .

Abstract

Background/Objectives: Childhood cancer survivors (CCS) experience chronic health problems and significant metabolic burden. Timely identification of CCS at higher metabolic risk requires novel biomarkers. Irisin, a novel myokine/adipokine has been associated with metabolic, bone and reproductive diseases, but its role in the health of CCS is unknown. The aim of this study was to examine irisin concentrations in children and adolescent CCS (vs. controls) and their association with metabolic, bone and hormonal parameters. Methods: Children and adolescent CCS, aged 8-18 years, as well as healthy controls, underwent a detailed physical, body composition, biochemical, hormonal and serum irisin assessment at least 6 months post-treatment. Results: A total of 59 children and adolescents (36 CCS, 23 controls; mean age ± SD 12.8 ± 2.9 years; 10 prepubertal, 49 pubertal) participated in the study. Serum irisin concentrations (ng/mL) were significantly lower in CCS than controls [median (IQR) 6.54 (4.12) vs. 11.70 (8.75) ng/mL, respectively, p < 0.001]. In the total study sample, serum irisin was correlated negatively with LH (rs = -0.314, p < 0.05), CRP (rs = -0.366, p < 0.005), age (rs = -0.323, p < 0.05) and positively with ALP (rs = 0.328, p < 0.05). Serum irisin was also positively correlated with ApoB and Lpa (rs = 0.410 and 0.421, respectively, p < 0.05) in CCS, and with PTH (r = 0.542, p < 0.005) in controls. Multivariate linear regression analysis indicated parathyroid hormone (PTH) as the only independent variable affecting irisin concentrations. Conclusions: Study results reinforce the irisin-PTH interplay hypothesis. Future studies are needed to clarify the potential role of irisin as a bone biomarker of CCS in childhood and adolescence.

Keywords: PTH; adolescents; cancer survivors; childhood cancer survivors; children; irisin; parathyroid hormone.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Irisin concentrations in CCS and controls.
See this image and copyright information in PMC

References

    1. Marzorati C., Riva S., Pravettoni G. Who Is a Cancer Survivor? A Systematic Review of Published Definitions. J. Cancer Educ. 2017;32:228–237. doi: 10.1007/s13187-016-0997-2. - DOI - PubMed
    1. Siegel D.A., King J.B., Lupo P.J., Durbin E.B., Tai E., Mills K., Van Dyne E., Buchanan Lunsford N., Henley S.J., Wilson R.J. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003–2019. J. Natl. Cancer Inst. 2023;115:1337–1354. doi: 10.1093/jnci/djad115. - DOI - PMC - PubMed
    1. Siegel R.L., Miller K.D., Wagle N.S., Jemal A. Cancer statistics, 2023. CA Cancer J. Clin. 2023;73:17–48. doi: 10.3322/caac.21763. - DOI - PubMed
    1. Bhakta N., Liu Q., Ness K.K., Baassiri M., Eissa H., Yeo F., Chemaitilly W., Ehrhardt M.J., Bass J., Bishop M.W., et al. The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE) Lancet. 2017;390:2569–2582. doi: 10.1016/S0140-6736(17)31610-0. - DOI - PMC - PubMed
    1. Bhatia S., Tonorezos E.S., Landier W. Clinical Care for People Who Survive Childhood Cancer: A Review. Jama. 2023;330:1175–1186. doi: 10.1001/jama.2023.16875. - DOI - PubMed

LinkOut - more resources